Full history for every metric is available with a Kvantra account
BioDelivery Sciences International, Inc. (BDSI)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 16 | 62 | 56 | 111 | 156 | 167 | 167 |
| Operating profit | $m | 37 | 37 | |||||
| Net profit | $m | -67 | 5 | -34 | -15 | 26 | 85 | 85 |
| EPS reported | $ | 0.82 | 0.82 | |||||
| Operating cashflow per share | $ | 0.40 | 0.40 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | 0.39 | 0.39 | |||||
| Free cash flow | $m | 41 | 41 | |||||
| Net debt | $m | -56 | -56 | |||||
| Book value equity | $m | 188 | 188 | |||||
| Book value per share | $ | 1.82 | 1.82 | |||||
| Number of shares | m | 103.29 | 103.29 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 3.78 | - | |||||
| P/B LTM | x | 1.70 | 3.07 | |||||
| P/S LTM | x | 1.92 | 3.46 | |||||
| P/FCF LTM | x | 7.88 | 14.06 | |||||
| EV/EBITDA LTM | x | 5.94 | 11.71 | |||||
| EV/Sales LTM | x | 1.59 | 3.13 | |||||
| Earnings Yield LTM | % | 26.46% | 14.70% | |||||
| FCF Yield | % | 12.69% | 7.11% | |||||
| Quality | ||||||||
| ROE | % | 45.18% | 57.33% | |||||
| ROIC | % | 15.04% | 15.04% | |||||
| Operating margin | % | 22.27% | 22.27% | |||||
| Gross margin | % | 85.98% | 85.98% | |||||
| FCF/Sales | % | 24.37% | 24.37% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +241.67% | +241.67% | |||||
| Sales Growth YoY | % | +6.54% | +6.54% | |||||
| Net Income Growth YoY | % | +230.05% | +230.05% | |||||
| FCF Growth | % | +62.70% | +62.70% | |||||
| Operating Profit Growth | % | +12.57% | +12.57% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.69 | 0.70 | |||||
| Net Debt/EBITDA | x | -1.25 | -1.25 | |||||
| EBIT/Net interest | x | 4.95 | 4.95 | |||||
| Net debt/market cap | % | -17.34% | -9.62% | |||||
| Net debt/Equity | x | -0.30 | -0.30 | |||||
| Gross debt/equity | x | 0.31 | 0.31 | |||||
Company overview
BioDelivery Sciences International, Inc. (BDSI) is a specialized pharmaceutical firm dedicated to the advancement and commercialization of therapeutic products designed for long-term health conditions, serving markets both within the United States and internationally. The company's product offerings leverage its proprietary BioErodible MucoAdhesive drug delivery system—a slender, dissolving polymer film intended for application to the inner cheek—in addition to other drug administration methodologies. Its portfolio includes several key products: BELBUCA, a buprenorphine buccal film, is utilized for the ongoing management of persistent pain. Symproic functions as a peripherally acting mu-opioid receptor antagonist, specifically addressing opioid-induced constipation in adult patients suffering from chronic non-cancer pain. This also covers individuals whose chronic pain is a result of prior cancer or its treatment, provided they do not require frequent increases in opioid dosage. ELYXYB, an oral solution containing celecoxib, provides treatment for adult migraines, irrespective of the presence of an aura. ONSOLIS, a soluble fentanyl film administered buccally, is intended for the management of sudden, severe "breakthrough" pain experienced by cancer patients. Founded in 1997, BioDelivery Sciences International, Inc. is headquartered in Raleigh, North Carolina. As of March 18, 2022, the company operates as a subsidiary of Collegium Pharmaceutical, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BioDelivery Sciences International, Inc. (BDSI)
BioDelivery Sciences International, Inc. (BDSI) is a specialized pharmaceutical firm dedicated to the advancement and commercialization of therapeutic products designed for long-term health conditions, serving markets both within the United States and internationally. The company's product offerings leverage its proprietary BioErodible MucoAdhesive drug delivery system—a slender, dissolving polymer film intended for application to the inner cheek—in addition to other drug administration methodologies. Its portfolio includes several key products: BELBUCA, a buprenorphine buccal film, is utilized for the ongoing management of persistent pain. Symproic functions as a peripherally acting mu-opioid receptor antagonist, specifically addressing opioid-induced constipation in adult patients suffering from chronic non-cancer pain. This also covers individuals whose chronic pain is a result of prior cancer or its treatment, provided they do not require frequent increases in opioid dosage. ELYXYB, an oral solution containing celecoxib, provides treatment for adult migraines, irrespective of the presence of an aura. ONSOLIS, a soluble fentanyl film administered buccally, is intended for the management of sudden, severe "breakthrough" pain experienced by cancer patients. Founded in 1997, BioDelivery Sciences International, Inc. is headquartered in Raleigh, North Carolina. As of March 18, 2022, the company operates as a subsidiary of Collegium Pharmaceutical, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free